We are live on ! Find out more
OXFD

Oxford Immunotec Global PLC Ordinary Shares
OXFD

Delisted

OXFD was delisted on the 5th of March, 2021.

73 hedge funds and large institutions have $274M invested in Oxford Immunotec Global PLC Ordinary Shares in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 1

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

30% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 23

23% more capital invested

Capital invested by funds: $223M → $274M (+$51.2M)

18% more funds holding

Funds holding: 6273 (+11)

Holders
73
Holders Change
+11
Holders Change %
+17.74%
% of All Funds
1.82%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
12
Increased
30
Reduced
23
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$402K +$54.7K +3,900 +17%
WSA
52
Wall Street Associates
California
$341K
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$320K -$47.8K -3,407 -14%
DIA
54
Denver Investment Advisors
Colorado
$313K +$294K +20,931 New
Deutsche Bank
55
Deutsche Bank
Germany
$307K -$120K -8,538 -29%
ECM
56
Endurant Capital Management
California
$240K -$1.34M -95,599 -86%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$227K -$2.75K -196 -1%
Citadel Advisors
58
Citadel Advisors
Florida
$215K +$202K +14,375 New
NFA
59
Nationwide Fund Advisors
Ohio
$202K
Goldman Sachs
60
Goldman Sachs
New York
$194K -$65.7K -4,682 -27%
AIG
61
American International Group
New York
$191K -$477 -34 -0.3%
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
$187K +$48.5K +3,458 +38%
PCM
63
Prelude Capital Management
New York
$187K +$176K +12,537 New
TC
64
TFS Capital
Pennsylvania
$176K +$165K +11,788 New
VOYA Investment Management
65
VOYA Investment Management
Georgia
$172K
BA
66
BlackRock Advisors
Delaware
$124K +$8.97K +639 +8%
Legal & General Group
67
Legal & General Group
United Kingdom
$96K +$90.4K +6,440 New
UBS Group
68
UBS Group
Switzerland
$62K +$46.1K +3,284 +367%
Bank of America
69
Bank of America
North Carolina
$57K +$33.5K +2,386 +166%
BlackRock
70
BlackRock
New York
$33K -$3.9K -278 -11%
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$21K +$19.5K +1,391 New
BNP Paribas Financial Markets
72
BNP Paribas Financial Markets
France
$17.6K -$6.54K -466 -28%
Barclays
73
Barclays
United Kingdom
$2K -$2.23K -159 -58%
Prudential Financial
74
Prudential Financial
New Jersey
-$139K -11,090 Closed

OXFD Hedge Fund Activity: Q4 2016 in Review

73 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q4 2016, worth a combined $274M — up 23% from $223M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new OXFD positions and 1 closed out — a net gain of 11 holders — while 30 added to existing stakes and 23 trimmed.

The largest buyer was RTW Investments, adding an estimated $4.31M. The largest seller was Clarus Ventures, cutting an estimated $13.9M.

  • 73 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q4 2016, up from 62 in Q3 2016.
  • Funds reported $274M of Oxford Immunotec Global PLC Ordinary Shares stock for Q4 2016, up 23% quarter-over-quarter.
  • 12 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q4 2016 and 1 closed out, a net change of +11 holders.
  • The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q4 2016 was RTW Investments, an estimated $4.31M added.
  • The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q4 2016 was Clarus Ventures, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2016.